Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep-Oct;1(5):432-8.
doi: 10.4161/mabs.1.5.9497. Epub 2009 Sep 10.

Tocilizumab

Adith Venkiteshwaran  1
Affiliations
Review

Tocilizumab

Adith Venkiteshwaran. MAbs. 2009 Sep-Oct.

Abstract

Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.

PubMed Disclaimer

References

    1. Strand V, Kimberly R, Isaacs J. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Disc. 2007;6:75–92. - PubMed
    1. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol. 2001;19:163–196. - PubMed
    1. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R downregulation of Type II collagen, aggrecan core and link protein transcription in articular chondrocytes: association with a downregulation of SOX9 expression. J Biol Chem. 2003;278:2903–2912. - PubMed
    1. De Hooge AS, van de Loo FA, Arntz OJ, van den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol. 2000;157:2081–2091. - PMC - PubMed
    1. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNFα, IL-1 and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004;114:582–588. - PMC - PubMed